Merck Up On Q1, Januvia Report; Bristol, Pfizer Mixed

By | April 28, 2015

Scalper1 News

Merck (MRK) stock jumped more than 5% Tuesday as the company led a trio of big pharmas reporting first-quarter earnings, bolstered by good news on its diabetes franchise. Merck reported earnings of 85 cents a share, down 3% from the year-earlier quarter but 10 cents better than analysts’ consensus. Sales shrank 8% to $9.43 billion, beating consensus by nearly $400 million. Investors were also in a buoyant mood after Merck announced late Monday Scalper1 News

Scalper1 News